CMV is a very common viral infection which remains latent in an infected person’s body throughout their life.
While it generally does not cause problems in a healthy, functioning immune system, it can have serious consequences for immunocompromised people (e.g, newborn babies, for-sample, SOT and HSCT transplant setting.)
It is the most common viral infection in solid organ transplant (SOT) recipients, between 20-60% of whom develop a symptomatic CMV infection, typically during the first few months after transplantation. The virus can be reactivated in a patient who already has the infection, or a patient can be infected through the donor organ.
Roche is committed to helping deter the spread and reactivation of CMV, and its harmful consequences, with a range of systems and assays to detect and monitor the progression of CMV infections.